VTS-72 aims to be the next generation oral fumarate therapy, that may hold potential as a treatment for MS with fewer side effects and other clinical benefits for these patients.
Aiming to submit NDA in 2020-2021.
What is Flush?
First Patient Dosed in Pilot Study of Vitalis’ VTS-K for Acute Musculoskeletal Pain
Tuesday, January 12th, 2021 8:00 am ET
Vitalis to Present at the H.C. Wainwright 22nd Annual Global Investment Conference
Tuesday, September 1st, 2020 8:00 am ET
Vitalis Receives Orphan Drug Designation for Diroximel Fumarate and Monomethyl Fumarate, in Combination with VTS-Aspirin, for Multiple Sclerosis Patients Who Experience Fumarate Flush
Tuesday, April 21st, 2020 8:00 am ET
Vitalis Pharmaceuticals Announces Results of Type C Meeting with FDA for VTS-72
Tuesday, January 7th, 2020 8:00 am ET
Vitalis Pharmaceuticals Anticipates Launch of Novel Low-Flush Fumarate by 2021
Tuesday, October 22nd, 2019 8:00 am ET